Savolitinib with durvalumab for treating unresectable locally advanced or metastatic MET-driven papillary renal cell carcinoma

Savolitinib in combination with durvalumab is currently in clinical development for the treatment of patients with unresectable and locally advanced or metastatic mesenchymal-epithelial transition (MET)-driven papillary renal cell carcinoma (PRCC). Renal cell carcinoma is a common type of kidney cancer. Unresectable means the cancer cannot be removed with surgery. Locally advanced means the cancer has spread into the surrounding area. Metastatic cancer means cells have broken away from the original (primary) tumour and travelled around the body to form tumours in new regions. In most cases of locally advanced PRCC, surgery is not possible and therapeutic options are often limited meaning there is an unmet clinical need.